Role of the low-density lipoprotein receptor-related protein in β- amyloid metabolism and Alzheimer disease

Archives of Neurology

Volumn 57, Issue 5, 2000, Pages 646-650

  Hyman, Bradley T ^a   Strickland, Dudley ^b   Rebeck, G William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ALZHEIMER DISEASE; DNA POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN METABOLISM; REVIEW;

EID: 0034122869     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.5.646     Document Type: Review

References (84)

1. Terry RD, Masliah E, Salmon DP. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;41:572-580.
2. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17-24.
3. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447-453.
4. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
5. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973-977.
6. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775-778.
7. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
8. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci U S A. 1997;94:2095-2097.
9. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993;52:594-600.
10. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055-1058.
11. Cruz L, Urbanc B, Buldyrev SV, et al. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:7612-7616.
12. Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol. 1992;140:1389-1399.
13. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553-565.
14. Du Van S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:5296-5301.
15. Willnow TE, Moehring JM, Inocencio NM, Moehring TJ, Herz J. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Biochem J. 1996;313:71-76.
16. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988;7:4119-4127.
17. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 1990;265:17401-17404.
18. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11:575-580.
19. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa Protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem. 1991;266:21232-21238.
20. Williams SE, Ashcom JD, Argraves WS, Strickland DK. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein: multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem. 1992;267:9035-9040.
21. Medved LV, Migliorini M, Mikhailenko I, Barrientos LG, Llinas M, Strickland DK. Domain organization of the 39-kDa receptor-associated protein. J Biol Chem. 1999;274:717-727.
22. Mahley RW, Nathan BP, Pitas RE. Apolipoprotein E: structure, function, and possible roles in Alzheimer's disease. Ann N Y Acad Sci. 1996;777:139-145.
23. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989;341:162-164.
24. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163-166.
25. Wisniewski T, Frangione B, Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235-238.
26. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
27. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
28. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993;342:697-699.
29. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol. 1993;34:752-754.
30. Hyman BT. Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease. J Am Geriatr Soc. 1996;44:1469-471.
31. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994;17:525-530.
32. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850-852.
33. Holtzman DM, Pitas RE, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A. 1995;92:9480-9484.
34. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:11183-11186.
35. Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92-94.
36. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860-869.
37. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030-1035.
38. Castano EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306:599-604.
39. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649-9653.
40. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242-1247.
41. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996;39:62-70.
42. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254-259
43. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun. 1993;192:359-365.
44. Naslund J, Thyberg J, Tjernberg LO, et al. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron. 1995;15:219-228.
45. LaDu MJ, Lukens JR, Reardon CA, Getz GS. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 1997;49:9-18.
46. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci. 1998;18:195-204.
47. Urmoneit B, Prikulis I, Wihl G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 1997;77:157-166.
48. Du Y, Ni B, Glinn M, et al. Alpha2-macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997;69:299-305.
49. Du Y, Bales KR, Dodel RC, et al. Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem. 1998;70:1182-1188.
50. Hughes SR, Khorkova O, Goyal S, et al. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A. 1998;95:3275-3280.
51. Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem. 1996;271:8443-8451.
52. Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904-1911.
53. Qiu Z, Strickland D, Hyman B, Rebeck G. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta amyloid peptide via the low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. 1999;73:1393-1398.
54. Morrot A, Strickland DK, Higuchi MdL, Reis M, Pedrosa R, Scharfstein J. Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes. Int Immunol. 1997;9:825-834.
55. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
56. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357-360.
57. Liao A, Nitsch RM, Greenberg SM, et al. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet. 1998;7:1953-1956.
58. Wavrant-DeVrieze F, Rudrasingham V, Lambert JC, et al. No association between the alpha-2 macroglobulin l1000V polymorphism and Alzheimer's disease. Neurosci Lett. 1999;262:137-139.
59. Rudrasingham V, Wavrant-De Vrieze F, Lambert JC, et al. Alpha-2 macroglobulin gene and Alzheimer disease [letter]. Nat Genet. 1999;22:17-19.
60. Rogaeva EA, Premkumar S, Grubber J, et al An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease [letter]. Nat Genet. 1999;22:19-20.
61. Dow DJ, Lindsey N, Cairns NJ, et al. Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK [letter]. Nat Genet. 1999;22:16-17.
62. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331-340
63. Knauer MF, Orlando RA, Glabe CG. Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related prolein (LRP). Brain Res. 1996;740:6-14.
64. Perez R, Soriano S, Hayes J, et al. Mutagenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ42. J Biol Chem. 1999;274:18851-18856.
65. Ulery PG, Beers J, Mikhailenko I, et al. Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP) evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000;275:7410-7415.
66. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556-33560.
67. Fiore F, Zambrano N, Minopoli G, Donini V, Duilio A, Russo T. The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of She bind the intracellular domain of the Alzheimer's amyloid precursor protein. J Biol Chem. 1995;270:30853-30856.
68. Guenette SY, Chen J, Jondro PD, Tanzi RE. Association of a novel human FE65-like protein with the cytoplasmic domain of the beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 1996;93:10832-10837.
69. Bressler SL, Gray MD, Sopher BL, et al. cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. Hum Mol Genet. 1996;5:1589-1598.
70. Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol. 1996;16:6229-6241.
71. McLoughlin DM, Miller CC. The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. FEBS Lett. 1996;397:197-200.
72. Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol. 1999;19:5179-5188.
73. Wavrant-DeVrieze F, Perez-Tur J, Lambert JC, et al. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett. 1997;227:68-70.
74. Clatworthy AE, Gomez-Isla T, Rebeck GW, Wallace RB, Hyman BT. Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol. 1997;54:1289-1292.
75. Fallin D, Kundtz A, Town T, et al. No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neurosci Lett. 1997;233:145-147.
76. Lendon CL, Talbot CJ, Craddock NJ, et al. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett. 1997;222:187-190.
77. Kang DE, Saitoh T, Chen X, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997;49:56-61.
78. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease Neurology. 1998;50:1905-1907.
79. Baum L, Chen L, Ng HK, et al. Low density lipoprotein receptor related protein gene exon 3 polymorphism association with Alzheimer's disease in Chinese. Neurosci Lett. 1998;247:33-36.
80. Tooyama I, Kawamata T, Akiyama H, Moestrup SK, Gliemann J, McGeer PL. Immunohistochemical study of alpha 2 macroglobulin receptor in Alzheimer and control postmortem human brain. Mol Chem Neuropathol. 1993;18:153-160.
81. Thal DR, Schober R, Birkenmeier G. The subunits of alpha2-macroglobulin receptor/ low density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and interleukin 6 in Alzheimer's disease. Brain Res. 1997;777:223-227.
82. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211-217.
83. Hollister RD, Kisiel W, Hyman BT. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Brain Res. 1996;728:13-19.
84. Postuma RB, Martins RN, Cappai R, et al. Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. FEBS Lett. 1998;428:13-16.